Literature DB >> 22642591

Prevalence of 1691G>A FV mutation in Poland compared with that in other Central, Eastern and South-Eastern European countries.

Grażyna Adler1, Jeremy S C Clark, Beata Loniewska, Ewa Czerska, Nermin N Salkic, Andrzej Ciechanowicz.   

Abstract

The 1691G>A FV variant has been described as a common genetic risk factor in venous thromboembolism. The purpose of this study was to provide a further frequency value for 1691G>A FV in Poland and to collate summary data from Central (Poland, Czech, Slovakia), Eastern (Russia, Belarus, Ukraine) and South-Eastern (Slovenia, Croatia, Bosnia and Herzegovina, Serbia, Montenegro, Macedonia, Bulgaria) European countries. For this purpose in 2007 the 1691G>A FV variant was analyzed by polymerase chain reaction-restriction fragment length polymorphism from DNA collected in 2005-2006. We studied 650 subjects: 400 newborns and 250 older individuals (mean age 46.1 y) from Poland and compared results with reports from other countries, as well as with the frequency trend of 845G>A HFE across South-Eastern European countries using centroid cities. From our 1691G>A FV study we identified 626 GG homozygotes, 23 GA heterozygotes, and 1 AA homozygote (n = 650), giving an A allele frequency of 1.9%, and a summed frequency value for Poland of 2.0% (n = 1588); the frequency in Central European countries was 3.9% (n = 4559), mostly due to the high value in the Czech Republic: 5.1% (n = 2819); the South-Eastern European countries had 2.5% (n = 2410). Among the Eastern European countries the 1691G>A FV allele frequency was 1.9% (n=791), between the South-Eastern and Eastern European countries there was no significant difference (p=0.17). We confirm that the 1691G>A FV allele frequency in Poland, as well as other countries compared, is significantly lower than that in Czech.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22642591      PMCID: PMC4362443          DOI: 10.17305/bjbms.2012.2500

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  53 in total

1.  Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.

Authors:  D Mikovic; L Rakicevic; M Kovac; D Radojkovic
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

2.  Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease.

Authors:  D Petrovic; M Zorc; I Keber; B Peterlin
Journal:  Ann Genet       Date:  2001 Jan-Mar

3.  Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages.

Authors:  Z J Foka; A F Lambropoulos; H Saravelos; G B Karas; A Karavida; T Agorastos; V Zournatzi; P E Makris; J Bontis; A Kotsis
Journal:  Hum Reprod       Date:  2000-02       Impact factor: 6.918

4.  Homogeneity and distinctiveness of Polish paternal lineages revealed by Y chromosome microsatellite haplotype analysis.

Authors:  Rafal Ploski; Marcin Wozniak; Ryszard Pawlowski; Dorota Marta Monies; Wojciech Branicki; Tomasz Kupiec; Ate Kloosterman; Tadeusz Dobosz; Elena Bosch; Magdalena Nowak; Rüdiger Lessig; Mark A Jobling; Lutz Roewer; Manfred Kayser
Journal:  Hum Genet       Date:  2002-05-22       Impact factor: 4.132

5.  Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.

Authors:  D Coen; R Zadro; L Honović; L Banfić; A Stavljenić Rukavina
Journal:  Croat Med J       Date:  2001-08       Impact factor: 1.351

6.  Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis.

Authors:  B Boyanovsky; M Russeva; V Ganev; M Penev; M Baleva; M Russev
Journal:  Blood Coagul Fibrinolysis       Date:  2001-12       Impact factor: 1.276

7.  Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke.

Authors:  S Lopaciuk; K Bykowska; H Kwiecinski; A Mickielewicz; A Czlonkowska; T Mendel; A Kuczynska-Zardzewialy; D Szelagowska; J Windyga; W Schröder; F H Herrmann; H Jedrzejowska
Journal:  Clin Appl Thromb Hemost       Date:  2001-10       Impact factor: 2.389

8.  Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis.

Authors:  E Nizankowska-Mogilnicka; L Adamek; P Grzanka; T B Domagala; M Sanak; M Krzanowski; A Szczeklik
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

9.  Polymorphisms in various coagulation genes in black South African women with placental abruption.

Authors:  B Hira; R J Pegoraro; L Rom; T Govender; J Moodley
Journal:  BJOG       Date:  2002-05       Impact factor: 6.531

Review 10.  Factor V Leiden thrombophilia.

Authors:  Jody Lynn Kujovich
Journal:  Genet Med       Date:  2011-01       Impact factor: 8.822

View more
  4 in total

1.  Prevalence of 1691G>A FV mutation in females from Bosnia and Herzegovina--a preliminary report.

Authors:  Amina Valjevac; Bakir Mehić; Emina Kiseljaković; Slavka Ibrulj; Agnieszka Garstka; Grażyna Adler
Journal:  Bosn J Basic Med Sci       Date:  2013-02       Impact factor: 3.363

2.  Allele frequency distribution of 1691G >A F5 (which confers Factor V Leiden) across Europe, including Slavic populations.

Authors:  Jeremy S C Clark; Grażyna Adler; Nermin N Salkic; Andrzej Ciechanowicz
Journal:  J Appl Genet       Date:  2013-11       Impact factor: 3.240

3.  Vascular Genetic Variants and Ischemic Stroke Susceptibility in Albanians from the Republic of Macedonia.

Authors:  Bajram Kamberi; Farije Kamberi; Mirko Spiroski
Journal:  Open Access Maced J Med Sci       Date:  2016-10-01

4.  Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina.

Authors:  Adna Ašić; Ramona Salazar; Niels Storm; Serkan Doğan; Wolfgang Höppner; Damir Marjanović; Dragan Primorac
Journal:  Croat Med J       Date:  2019-06-13       Impact factor: 1.351

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.